Table 3.
Initial Treatment Option Data for Age-related Macular Degeneration, 2011–2018
| Year | Treated Cases (%) | Initial Treatment Option (%) |
||
|---|---|---|---|---|
| Anti-VEGF Therapy | PDT | Combination | ||
| 2011 | 16 411 (100) | 13 165 (80.2) | 2304 (14.0) | 942 (5.7) |
| 2012 | 21 564 (100) | 18 495 (85.8) | 2129 (9.9) | 940 (4.4) |
| 2013 | 28 215 (100) | 26 218 (92.9) | 1513 (5.4) | 484 (1.7) |
| 2014 | 34 588 (100) | 32 740 (94.7) | 1468 (4.2) | 380 (1.1) |
| 2015 | 35 478 (100) | 33 741 (95.1) | 1439 (4.1) | 298 (0.8) |
| 2016 | 35 141 (100) | 33 513 (95.4) | 1342 (3.8) | 286 (0.8) |
| 2017 | 37 255 (100) | 35 411 (95.1) | 1444 (3.9) | 400 (1.1) |
| 2018 | 37 412 (100) | 35 382 (94.6) | 1445 (3.9) | 585 (1.6) |
| Total | 246 064 (100) | 228 665 (92.9) | 13 084 (5.3) | 4315 (1.8) |
PDT = photodynamic therapy with verteporfin; VEGF = vascular endothelial growth factor.